vs
Side-by-side financial comparison of LandBridge Co LLC (LB) and PUMA BIOTECHNOLOGY, INC. (PBYI). Click either name above to swap in a different company.
PUMA BIOTECHNOLOGY, INC. is the larger business by last-quarter revenue ($75.5M vs $56.8M, roughly 1.3× LandBridge Co LLC). On growth, LandBridge Co LLC posted the faster year-over-year revenue change (55.6% vs 27.7%). LandBridge Co LLC produced more free cash flow last quarter ($122.0M vs $14.4M). Over the past eight quarters, LandBridge Co LLC's revenue compounded faster (72.8% CAGR vs 31.3%).
Puma Biotechnology is a publicly traded biopharmaceutical company headquartered in Los Angeles, CA.
LB vs PBYI — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $56.8M | $75.5M |
| Net Profit | $8.1M | — |
| Gross Margin | — | 69.3% |
| Operating Margin | 60.0% | 22.7% |
| Net Margin | 14.2% | — |
| Revenue YoY | 55.6% | 27.7% |
| Net Profit YoY | -83.7% | — |
| EPS (diluted) | $0.24 | $0.26 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $56.8M | $75.5M | ||
| Q3 25 | $50.8M | $54.5M | ||
| Q2 25 | $47.5M | $52.4M | ||
| Q1 25 | $44.0M | $46.0M | ||
| Q4 24 | $36.5M | $59.1M | ||
| Q3 24 | $28.5M | $80.5M | ||
| Q2 24 | $26.0M | $47.1M | ||
| Q1 24 | $19.0M | $43.8M |
| Q4 25 | $8.1M | — | ||
| Q3 25 | $8.1M | $8.8M | ||
| Q2 25 | $7.5M | $5.9M | ||
| Q1 25 | $6.5M | $3.0M | ||
| Q4 24 | $49.3M | — | ||
| Q3 24 | $2.7M | $20.3M | ||
| Q2 24 | $-57.7M | $-4.5M | ||
| Q1 24 | $10.8M | $-4.8M |
| Q4 25 | — | 69.3% | ||
| Q3 25 | — | 77.7% | ||
| Q2 25 | — | 76.5% | ||
| Q1 25 | — | 77.1% | ||
| Q4 24 | — | 76.4% | ||
| Q3 24 | — | 63.9% | ||
| Q2 24 | — | 77.4% | ||
| Q1 24 | — | 75.5% |
| Q4 25 | 60.0% | 22.7% | ||
| Q3 25 | 60.8% | 17.6% | ||
| Q2 25 | 60.0% | 12.7% | ||
| Q1 25 | 57.0% | 8.7% | ||
| Q4 24 | 49.4% | 22.6% | ||
| Q3 24 | 11.2% | 27.4% | ||
| Q2 24 | -197.4% | -4.6% | ||
| Q1 24 | 71.1% | -5.3% |
| Q4 25 | 14.2% | — | ||
| Q3 25 | 15.9% | 16.2% | ||
| Q2 25 | 15.8% | 11.2% | ||
| Q1 25 | 14.7% | 6.5% | ||
| Q4 24 | 135.2% | — | ||
| Q3 24 | 9.3% | 25.2% | ||
| Q2 24 | -222.1% | -9.6% | ||
| Q1 24 | 56.7% | -11.0% |
| Q4 25 | $0.24 | $0.26 | ||
| Q3 25 | $0.26 | $0.17 | ||
| Q2 25 | $0.24 | $0.12 | ||
| Q1 25 | $0.20 | $0.06 | ||
| Q4 24 | — | $0.40 | ||
| Q3 24 | $-0.04 | $0.41 | ||
| Q2 24 | — | $-0.09 | ||
| Q1 24 | — | $-0.10 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $30.7M | $97.5M |
| Total DebtLower is stronger | $570.7M | $22.7M |
| Stockholders' EquityBook value | $340.3M | $130.3M |
| Total Assets | $1.4B | $216.3M |
| Debt / EquityLower = less leverage | 1.68× | 0.17× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $30.7M | $97.5M | ||
| Q3 25 | $28.3M | $94.4M | ||
| Q2 25 | $20.3M | $96.0M | ||
| Q1 25 | $14.9M | $93.2M | ||
| Q4 24 | $37.0M | $101.0M | ||
| Q3 24 | $14.4M | $96.7M | ||
| Q2 24 | $24.6M | $96.8M | ||
| Q1 24 | — | $107.2M |
| Q4 25 | $570.7M | $22.7M | ||
| Q3 25 | $366.1M | $34.0M | ||
| Q2 25 | $370.9M | $45.3M | ||
| Q1 25 | $375.5M | $56.7M | ||
| Q4 24 | $385.5M | $68.0M | ||
| Q3 24 | $242.4M | $79.3M | ||
| Q2 24 | $360.8M | $90.7M | ||
| Q1 24 | — | $102.0M |
| Q4 25 | $340.3M | $130.3M | ||
| Q3 25 | $272.0M | $115.3M | ||
| Q2 25 | $266.4M | $104.7M | ||
| Q1 25 | $217.0M | $97.1M | ||
| Q4 24 | $211.8M | $92.1M | ||
| Q3 24 | $97.2M | $71.1M | ||
| Q2 24 | $296.4M | $48.5M | ||
| Q1 24 | $162.3M | $51.0M |
| Q4 25 | $1.4B | $216.3M | ||
| Q3 25 | $1.1B | $202.9M | ||
| Q2 25 | $1.1B | $194.9M | ||
| Q1 25 | $1.0B | $196.2M | ||
| Q4 24 | $1.0B | $213.3M | ||
| Q3 24 | $689.9M | $220.7M | ||
| Q2 24 | $710.5M | $205.0M | ||
| Q1 24 | — | $214.1M |
| Q4 25 | 1.68× | 0.17× | ||
| Q3 25 | 1.35× | 0.30× | ||
| Q2 25 | 1.39× | 0.43× | ||
| Q1 25 | 1.73× | 0.58× | ||
| Q4 24 | 1.82× | 0.74× | ||
| Q3 24 | 2.49× | 1.12× | ||
| Q2 24 | 1.22× | 1.87× | ||
| Q1 24 | — | 2.00× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $126.3M | $14.4M |
| Free Cash FlowOCF − Capex | $122.0M | $14.4M |
| FCF MarginFCF / Revenue | 214.9% | 19.1% |
| Capex IntensityCapex / Revenue | 7.5% | 0.0% |
| Cash ConversionOCF / Net Profit | 15.68× | — |
| TTM Free Cash FlowTrailing 4 quarters | $207.7M | $41.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $126.3M | $14.4M | ||
| Q3 25 | $34.9M | $9.7M | ||
| Q2 25 | $37.3M | $14.1M | ||
| Q1 25 | $15.9M | $3.6M | ||
| Q4 24 | $67.6M | $15.6M | ||
| Q3 24 | $7.5M | $11.0M | ||
| Q2 24 | $16.0M | $1.0M | ||
| Q1 24 | $17.2M | $11.2M |
| Q4 25 | $122.0M | $14.4M | ||
| Q3 25 | $33.7M | $9.7M | ||
| Q2 25 | $36.1M | $14.1M | ||
| Q1 25 | $15.8M | $3.6M | ||
| Q4 24 | $66.7M | $15.6M | ||
| Q3 24 | $7.1M | $11.0M | ||
| Q2 24 | $15.7M | $1.0M | ||
| Q1 24 | $17.1M | — |
| Q4 25 | 214.9% | 19.1% | ||
| Q3 25 | 66.3% | 17.7% | ||
| Q2 25 | 75.9% | 26.8% | ||
| Q1 25 | 36.0% | 7.7% | ||
| Q4 24 | 182.6% | 26.4% | ||
| Q3 24 | 25.1% | 13.7% | ||
| Q2 24 | 60.4% | 2.1% | ||
| Q1 24 | 90.1% | — |
| Q4 25 | 7.5% | 0.0% | ||
| Q3 25 | 2.3% | 0.0% | ||
| Q2 25 | 2.6% | 0.0% | ||
| Q1 25 | 0.2% | 0.1% | ||
| Q4 24 | 2.7% | 0.0% | ||
| Q3 24 | 1.1% | 0.0% | ||
| Q2 24 | 1.4% | 0.0% | ||
| Q1 24 | 0.5% | 0.0% |
| Q4 25 | 15.68× | — | ||
| Q3 25 | 4.31× | 1.10× | ||
| Q2 25 | 4.98× | 2.41× | ||
| Q1 25 | 2.46× | 1.21× | ||
| Q4 24 | 1.37× | — | ||
| Q3 24 | 2.80× | 0.54× | ||
| Q2 24 | — | — | ||
| Q1 24 | 1.60× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
